Date published: 2025-10-21

1-800-457-3801

SCBT Portrait Logo
Seach Input

Ruxolitinib (CAS 941678-49-5)

5.0(1)
Write a reviewAsk a question

See product citations (16)

Alternate Names:
Ruxolitinib is also known as INCB 018424.
Application:
Ruxolitinib is a potent Janus-associated kinase (JAK) inhibitor, selective to JAK1, JAK2, and JAK3.
CAS Number:
941678-49-5
Purity:
≥98%
Molecular Weight:
306.37
Molecular Formula:
C17H18N6
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Ruxolitinib is a synthetic compound that functions as a selective inhibitor of certain enzymes known as Janus kinases (JAKs). It is frequently utilized to study the JAK-STAT signaling pathway, which plays a pivotal role in the regulation of gene expression and cellular processes. By inhibiting JAK activity, this compound allows scientists to investigate the consequences of interrupted JAK-STAT pathway signaling, to understand of cellular responses to external stimuli. The modulation of kinase activity is critical to exploring the pathways involved in cell growth and division.


Ruxolitinib (CAS 941678-49-5) References

  1. The Janus kinases (Jaks).  |  Yamaoka, K., et al. 2004. Genome Biol. 5: 253. PMID: 15575979
  2. Ruxolitinib for myelofibrosis.  |  Gu, L., et al. 2013. Exp Ther Med. 5: 927-931. PMID: 23408184
  3. Ruxolitinib-associated infections: A systematic review and meta-analysis.  |  Lussana, F., et al. 2018. Am J Hematol. 93: 339-347. PMID: 29150886
  4. Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis.  |  Scuron, MD., et al. 2020. Front Immunol. 11: 620098. PMID: 33658996
  5. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.  |  Mozo, Y., et al. 2021. Pediatr Hematol Oncol. 38: 331-345. PMID: 33661711
  6. Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: A systematic review and meta-analysis.  |  Yu, DA., et al. 2021. Indian J Dermatol Venereol Leprol. 87: 621-627. PMID: 34379968
  7. Ruxolitinib-Associated Phaeohyphomycosis: A Case Report.  |  Marples, R., et al. 2021. Cureus. 13: e19335. PMID: 34765385
  8. A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis.  |  Zhang, Q., et al. 2022. Blood. 139: 3493-3504. PMID: 35344583
  9. Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2.  |  Song, Z., et al. 2022. J Transl Med. 20: 157. PMID: 35382859
  10. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.  |  Alvarez-Larrán, A., et al. 2022. Cancer. 128: 2441-2448. PMID: 35417564
  11. Ruxolitinib withdrawal complicating emergency aortic root replacement.  |  Szpytma, MM., et al. 2022. Interact Cardiovasc Thorac Surg. 35: PMID: 35640536
  12. Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis.  |  Fan, S., et al. 2022. Front Immunol. 13: 954268. PMID: 35990629
  13. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia.  |  Tan, Y., et al. 2023. J Hematol Oncol. 16: 34. PMID: 37020231
  14. The inhibition of glycolysis in T cells by a Jak inhibitor ameliorates the pathogenesis of allergic contact dermatitis in mice.  |  Okamoto, M., et al. 2023. J Invest Dermatol.. PMID: 37028703
  15. Jaks and STATs: biological implications.  |  Leonard, WJ. and O'Shea, JJ. 1998. Annu Rev Immunol. 16: 293-322. PMID: 9597132

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Ruxolitinib, 5 mg

sc-364729
5 mg
$246.00

Ruxolitinib, 25 mg

sc-364729A
25 mg
$490.00

Ruxolitinib, 25 mg

sc-364729A-CW
25 mg
$536.00

Puo essere utilizzato per malati di policitemia vera?

Asked by: francesco
Grazie per la domanda. Tutti i reagenti chimici e gli anticorpi offerti dalla Santa Cruz Biotechnology, Inc. sono forniti solo per ricerca di laboratorio in vitro (in-vitro RUO). I prodotti non sono destinati ad uso diagnostico o terapeutico e non devono essere utilizzati su animali o persone. Thank you for your question. All chemicals and antibodies offered by Santa Cruz Biotechnology, Inc. are supplied for laboratory in-vitro research use only (in-vitro RUO). The products are not intended for diagnostic or therapeutic use and must not be applied to animals or humans.
Answered by: Technical Support Europe
Date published: 2016-10-11
  • y_2025, m_10, d_14, h_6CST
  • bvseo_bulk, prod_bvqa, vn_bulk_3.0.42
  • cp_1, bvpage1
  • co_hasquestionsanswers, tq_1
  • loc_en_US, sid_364729, prod, sort_[SortEntry(order=LAST_APPROVED_ANSWER_SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-4.0.0
  • CLOUD, getContent, 119ms
  • QUESTIONS, PRODUCT
Rated 5 out of 5 by from Alimam et alAlimam et al. (PubMed ID 26343888) used Ruxolitinib to inhibit JAK1/2 in low-risk myelofibrosis patients. -SCBT Publication Review
Date published: 2015-02-27
  • y_2025, m_10, d_14, h_6
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.42
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_364729, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-4.0.0
  • CLOUD, getReviews, 9ms
  • REVIEWS, PRODUCT
Ruxolitinib is rated 5.0 out of 5 by 1.
  • y_2025, m_10, d_14, h_6
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.42
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_364729, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-4.0.0
  • CLOUD, getAggregateRating, 112ms
  • REVIEWS, PRODUCT